Efficacy of acitretin for porokeratosis in a child with chronic cutaneous graft versus host disease

Pediatr Dermatol. 2013 Jan-Feb;30(1):148-50. doi: 10.1111/j.1525-1470.2011.01610.x. Epub 2011 Nov 16.

Abstract

Porokeratosis is a rare disorder of epidermal keratinization that is regarded as a precancerous. Recipients of hematopoietic stem cell transplantation (HSCT) have a greater risk of skin cancer; chronic graft versus host disease (GVHD) is an additional risk factor. A 16-year-old boy who had received HSCT for acute myelogenous leukemia was referred to us for sclerodermoid chronic cutaneous GVHD. Two years later, he developed disseminated porokeratosis with a few atypical lesions. Despite cryotherapy, numerous lesions of porokeratosis recurred rapidly. Acitretin resulted in good clinical response and reduced the rate of onset of new lesions.

Publication types

  • Case Reports

MeSH terms

  • Acitretin / therapeutic use*
  • Adolescent
  • Biopsy, Needle
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / etiology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Immunohistochemistry
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / surgery*
  • Male
  • Porokeratosis / drug therapy*
  • Porokeratosis / etiology*
  • Porokeratosis / pathology
  • Risk Assessment
  • Treatment Outcome

Substances

  • Acitretin